Proceedings of the 2013 CINP summit: Innovative partnerships to accelerate CNS drug discovery for improved patient care

Abstract

Central nervous system (CNS) diseases and, in particular, mental health disorders, are becoming recognized as the health challenge of the 21st century. Currently, at least 10% of the global population is affected by a mental health disorder, a figure that is set to increase year on year. Meanwhile, the rate of development of new CNS drugs has not increased for many years, despite unprecedented levels of investment. In response to this state of affairs, the Collegium Internationale Neuro-Psychopharmacologicum (CINP) convened a summit to discuss ways to reverse this disturbing trend through new partnerships to accelerate CNS drug discovery. The objectives of the Summit were to explore the issues affecting the value chain (i.e. the chain of activities or stakeholders that a company engages in/with to deliver a product to market) in brain research, thereby gaining insights from key stakeholders and developing actions to address unmet needs; to identify achievable objectives to address the issues; to develop action plans to bring about measurable improvements across the value chain and accelerate CNS drug discovery; and fnally, to communicate recommendations to governments, the research and development community, and other relevant stakeholders. Summit outputs include the following action plans, aligned to the pressure points within the brain research-drug development value chain: 1. Code of conduct dealing with conlfict of interest issues, 2. Prevention, early diagnosis, and treatment, 3. Linking science and regulation, 4. Patient involvement in trial design, definition of endpoints, etc., 5. Novel trial design, 6. Reproduction and confirmation of data, 7. Update of intellectual property (IP) laws to facilitate repurposing and combination therapy (low priority), 8. Large-scale, global patient registries, 9. Editorials on nomenclature, biomarkers, and diagnostic tools, and 10. Public awareness, with brain disease advocates to attend G8 meetings and World Economic Forum (WEF) Annual meetings in Davos, Switzerland. In this context Professor Barbara Sahakian recently made a formal presentation at the World Economic Forum (see Barbara Sahakian Blog from April 11, 2014, at https://forumblog.org/people/barbara-sahakian/)